Unique Aberration-Free IOL:
A Vision that Patients
Can Appreciate
Akreos AO
An Aspheric Optic for
Improved Quality of Vision
n Traditional spherical IOLs create
Bilateral implantation study
spherical aberration and reduce
contrast sensitivity
High Order Aberrations at 3 months: 6mm pupil
n With Akreos AO, unique aspheric
2.00
anterior and posterior surfaces are
aberration neutral
1.80
1.60
n The result? Clinical outcomes
0.86
Total HOA
1.40
demonstrate a reduction in overall
higher order aberrations 1
coma
0.70
1.20
SA
1.00
n Contrast sensitivity under photopic
0.60
0.80
or mesopic lighting conditions
is similar to silicone aspheric
aberrated IOL2
0.52
0.60
0.40
0.50
0.20
0.35
0.00
Akreos Adapt
(n=32)
Akreos Adapt AO
(n=32)
G. Lofoco. Influence of Aspheric and Spherical IOLs on Higher-Order Aberrations and Functional Vision: Results of a
Comparative Multi-center Study. ASCRS 2006.
1
Bilateral implantation study
Mesopic Contrast Sensitivity: 3 cd/m2
120
120
100
100
Contrast Sensitivity
Contrast Sensitivity
Photopic Contrast Sensitivity: 85 cd/m2
80
60
40
60
40
20
20
0
0
1,5
3
6
12
18
1,5
Spatial Frequency (CPD)
Akreos AO (n=80)
2
80
3
6
12
18
Spatial Frequency (CPD)
Silicone Aspheric Aberrated IOL (n=80)
B. Johansson et al. Swedish multi-center study to compare the optical performance of the Akreos Adapt Advanced Optic (AO) IOL and the Tecnis Z9000. ASCRS 2006.
2
Akreos AO
Uniform Power Designed
to Work in Every Eye
n
No eye is optically perfect
The Natural Phakic Eye
n Constant power from centre to edge
helps to improve vision by providing
consistent power across the entire
optic surface
Iris
n Akreos AO is designed to provide
OPTICAL AXIS
(Cornea to Lens)
predictable, repeatable refractive
outcomes for all cataract patients,
regardless of corneal shape, pupil
size, as well as pupil or capsular
bag centration
VISUAL AXIS
(Object to Fovea)
Fovea
Lens
n Clinical results show excellent high
Retina
and low contrast BCVA comparable
to a middle-age phakic eye 3
All axes in the eye are not perfectly aligned and no two eyes are the same shape so you need IOLs that
work with imperfect conditions.
BCVA compared to phakic eyes
0.3
20/40
0.3
0.2
20/32
0.2
0.1
20/25
0.1
20/40
Akreos AO patients
(mean age: 70-year-old)
Akreos AO patients
(mean age: 70-year-old)
20/32
20/25
0
-0.1
IogMar
IogMar
6 months
20/20
Normal phakic
population
(mean age:
43-year-old)
6 months
1 year
-0.1
20/16
-0.2
20/20
Normal phakic
population
(mean age:
43-year-old)
20/16
-0.2
High Contrast (n=50)
3
0
1 year
Low Contrast (n=50)
V. Pfeifer. Clinical evaluation of a new aspheric IOL: the Akreos Adapt Advanced Optics (AO). Data from a pilot study at six months follow up. ASCRS 2006.
3
Akreos AO
Aberration-Free Design Helps
to Enhance Depth of Field
n The phakic eye has some natural
level of positive spherical aberration
n Positive spherical aberration helps
the phakic eye achieve better depth
of field
n Akreos AO maintains the natural,
positive spherical aberrations
compared to aspheric, aberrated
IOLs 2 (top figure)
n With its aberration-free design,
Akreos AO helps to significantly
improve depth of field in comparison
to an aspheric aberrated
IOL2 (bottom figure)
Natural Functionality
Bilateral implantation study
Spherical Aberrations
Depth of focus in intermediate vision
1
Akreos AO
Silicone Aspheric
Aberrated IOL
,8
RMS
,6
,4
,2
0
-.2
Z40 – 4mm
Z40 – 4,5mm
Corneal Peripheral rays
Mean Depth of Field4
p=0,03
Corneal Medium rays
Number of patients
Z40 – 5mm
Akreos AO
Silicone Aspheric
Aberrated IOL
0.85 Dpt
0.71 Dpt
74
74
Corneal Central rays
In intermediate vision more distant objects are seen through central corneal
rays whereas closer objects are seen through peripheral corneal rays.
4
2
. Johansson et al. Swedish multi-centre study to compare the optical performance of
B
the Akreos Adapt Advanced Optic (AO) IOL and the Tecnis Z9000. ASCRS 2006.
Measured with the Strehl ratio as described by S. Marcos et al. Implantation of Spherical and Aspheric IOLs. Journal of Refractive Surgery. May–June 2005; 21:1–13.
4
Akreos AO
A Visual Difference
Patients Appreciate
nA masked, subjective patient
nPatients had no way of knowing
assessment following cataract
surgery showed that twice as many
patients prefer the vision in their
Akreos AO eye2 (left figure)
which lens was implanted in
their eyes
nPatients also reported fewer visual
disturbances in their Akreos AO eye
compared to the silicone aspheric
aberrated IOL eye2 (right figure)
Bilateral implantation study: double-masked questionnaire
Any preference for one eye
Less dysphotopsia in one eye
40
40
30
30
20
20
Akreos AO
28%
10
Silicone
Aspheric
Aberrated IOL
14%
10
0
0
No difference 58%
(n=80)
2
Akreos AO
33%
Silicone
Aspheric
Aberrated IOL
11%
No difference 56%
(n=55)
B. Johansson et al. Swedish multi-centre study to compare the optical performance of the Akreos Adapt Advanced Optic (AO) IOL and the Tecnis Z9000. ASCRS 2006.
5
Akreos AO
For Optimised Effectiveness
against PCO
n The unique Square-Edge Technology
and a 360° posterior barrier reduce
cell migration following implantation
n EPCO analysis shows just how
effective the Akreos AO design
is in blocking cell growth 3
n Results are comparable to the
best performing acrylic IOLs5
Akreos Advanced Optics
EPCO Scores
@ 3 months
@ 6 months
@ 12 months
6mm optic area
0.048
0.048
0.048
3mm central area
0.007
0.008
0.012
(n=42)
(n=48)
(n=41)
EPCO Scores @ 12 months
Limit at which PCO does not require Nd:Yag capsulotomy*
Akreos AO
One-Piece Hydrophobic Acrylic Lens5
3
0.25
0.25
0.2
0.2
0.15
0.15
0.1
0.1
0.05
0.048
0.114
0.039
0.05
0.012
0
0
6mm optic area
(n=41)
3mm central area
(n=41)
6mm optic area
(n=123)
3mm central area
(n=123)
* Nd:Yag capsulotomy usually performed beyond 0.5 to 1.0, depending on PCO location and patient’s complaint.
3
5
V. Pfeifer. Clinical evaluation of a new aspheric IOL: the Akreos Adapt Advanced Optics (AO). Data from a pilot study at six months follow up. ASCRS 2006.
Data on file.
6
Akreos AO
Efficient Implantation through
an Unenlarged Phaco Incision
nThe Akreos Single-Use Insertion
Device enables implantation of
the Akreos AO through a 2.8mm
phaco incision
nImproved plunger design provides
symmetrical unfolding and easier
placement of the lead haptics into
the capsular bag
nThe flat loading, single-hand
injection makes quick work of
lens implantation
Single-Use Lens Delivery System
Akreos™ Single-Use Insertion Device AI-28B
1. Place the lens flat in to the loading deck
2. Close the injector and fit the tip
7
3. Advance the plunger and deliver the lens
Akreos Advanced Optics System
Model: Adapt AO
DIOPTER RANGE:
0.0 through 9.0 in 1.0 Dpt
MATERIAL:
26% acrylic material,
UV absorber, Refractive index: 1.458
(hydrated)
10.0 through 30.0 in 0.5 Dpt
LENS CONSTANTS:
ApplanationImmersion A-scan
A-scan
or IOL Master*
OPTIC:
A-Constant*
118.0 118.3 (SRK/T)
Biconvex aspheric anterior and
posterior, Optic body: 6mm
ACD*
4.96
5.18
Surgeon Factor* 1.22
1.40
HAPTICS:
ORDER CODES:
One-piece, 0º angulation
Lens in plastic vial:
ADAPTAOP or ADAPTAOTP
OVERALL DIAMETER:
11.0mm from 0.0 to 15.0 Dpt
10.7mm from 15.5 to 22.0 Dpt
Injector:
AI-28B
10.5mm from 22.5 to 30.0 Dpt
Belgium/Luxembourg Tel: +32 3 280 82 40
Fax: +32 3 280 82 59
Germany/
Switzerland/Austria
Tel: +49 30 33093 5431
Fax: +49 30 33093 5470
Portugal
Tel: +351 808 203 178
Fax: +351 808 203 179
Emerging Markets
Tel: +33 4 67 12 30 30
Fax: +33 4 67 12 30 32
Italy
Tel: +39 029 148 3851
Tel: +33 4 67 12 30 30
Fax: +33 4 67 12 30 31
Tel: +31 20 6554555
Fax: +31 20 655 4640
Tel: +34 902 381 010
Fax: +34 902 250 310
France
Netherlands
Spain
Nordic Countries
Tel: +46 8 616 95 00
Fax: +46 8 669 86 23
South Africa
Tel: +27 11 259 2600
Fax: +27 11 259 2650
United Kingdom
Tel: +44 20 8781 0000
Fax: +44 20 8781 0001
For information or Customer Service please contact your local representative or distributor.
Bausch & Lomb European Office, Bausch + Lomb House, 106–114 London Road, Kingston-upon-Thames, Surrey KT2 6TN, UK.
Tel: +44 20 8781 5500 Fax: +44 20 8781 2909
www.bauschsurgical.com
© 2011 Bausch & Lomb Incorporated / March2011 / version 2 / ® / ™ denote trademarks of Bausch & Lomb Incorporated
* A-Constant, ACD and Surgeon Factor are estimates only. Latest update March 2011. It is recommended that each surgeon
develop his or her own values.